2008•Bone Marrow TransplantationRequires access

Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML

Ram Malladi, Andy Peniket, Tim Littlewood, K. Towlson, Rachel Pearce, J. A. Liu Yin, Jamie Cavenagh, Charles Craddock, Kim Orchard, Eduardo Olavarría, Grant McQuaker, Matthew Collin, D I Marks, on behalf of the British Society of Blood and Marrow Transplantation

Open publisher page 34 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 34 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Alemtuzumab, Medicine, Internal medicine, Sibling, Transplantation, Gastroenterology, Surgery, Oncology